Evaluation of the Oral Antimitotic Agent (ABT-751) in Dogs with Lymphoma

Journal of Veterinary Internal Medicine

Volumn 26, Issue 2, 2012, Pages 349-354

  Silver, M ^a   Rusk, A ^a   Phillips, B ^c   Beck, E ^d   Jankowski, M ^e   Philibert, J ^f   Hahn, K ^g   Hershey, E ^h   McKeegan, E ^b   Bauch, J ^b   Krivoshik, A ^b   Khanna, C ^a  

^a Animal Clinical Investigation LLC   (United States)

^b ABBOTT LABORATORIES   (United States)

^c Veterinary Specialty Hospital   (United States)

^d Regional Veterinary Referral Center   (United States)

^e VCA Shoreline Veterinary Referral Emergency Center   (United States)

^f New England Veterinary Oncology Group   (United States)

^g Hill's Pet Nutrition Inc   (United States)

^h Arizona Veterinary Specialists   (United States)

Author keywords

Antiangiogenic; Antimitotic; Cancer; Treatment

Indexed keywords

ANTIMITOTIC AGENT; N [2 [(4 HYDROXYPHENYL)AMINO] 3 PYRIDINYL] 4 METHOXYBENZENESULFONAMIDE; SULFONAMIDE;

ANIMAL; ANIMAL DISEASE; ARTICLE; BLOOD; CLINICAL TRIAL; COHORT ANALYSIS; DOG; DOG DISEASE; DOSE RESPONSE; FEMALE; MALE; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; NONHODGKIN LYMPHOMA; ORAL DRUG ADMINISTRATION; PATHOLOGY; PHASE 1 CLINICAL TRIAL;

ADMINISTRATION, ORAL; ANIMALS; ANTIMITOTIC AGENTS; COHORT STUDIES; DOG DISEASES; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; LYMPHOMA, NON-HODGKIN; MALE; MAXIMUM TOLERATED DOSE; SULFONAMIDES;

ANIMALIA; CANIS FAMILIARIS;

EID: 84858753476     PISSN: 08916640     EISSN: 19391676     Source Type: Journal    
DOI: 10.1111/j.1939-1676.2012.00892.x     Document Type: Article

References (14)

1. Yoshimatsu K, Yamaguchi A, Yoshino H, et al. Mechanism of action of E7010, an orally active sulfonamide antitumor agent: Inhibition of mitosis by binding to the colchicine site of tubulin. Cancer Res 1997;57:3208-3213.
2. Koyanagi N, Nagasu T, Fujita F, et al. In vivo tumor growth inhibition produced by a novel sulfonamide, E7010, against rodent and human tumors. Cancer Res 1994;54:1702-1706.
3. Hande K, Hagey A, Berlin J, et al. The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimiotic agent: Results of a phase I study. Clin Cancer Res 2006;12:2834-2840.
4. Jordan M, Toso R, Thrower D, et al. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Cell Biol 1993;90:9552-9556.
5. Newman S, Foster P, Stengel C, et al. STX140 is efficacious in vitro and in vivo in taxane-resistant breast carcinoma cells. Clin Cancer Res 2008;14:597-606.
6. Funahashi Y, Koyanagi N, Kitoh K. Effect of E7010 on liver metastasis and life span of syngeneic C57BL/6 mice bearing orthotopically transplanted murine colon 38 tumor. Cancer Chemother Pharmacol 2001;47:179-184.
7. Yee K, Hagey A, Verstovsek S, et al. Phase I study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res 2005;11:6615-6624.
8. Fox E, Maris J, Widemann B, et al. A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 7 days every 21 days in pediatric patients with solid tumors. Clin Cancer Res 2006;12:4882-4887.
9. Fox E, Maris J, Widemann B. A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumors. Clin Cancer Res 2008;14:1111-1115.
10. Michels J, Ellard SL, Le L, et al. A phase IB study of ABT-751 in combination with docetaxel in patients with advanced castration-resistant prostate cancer. Ann Oncol 2010;21:305-11.
11. Mauer AM, Cohen EE, Ma PC, et al. A phase II study of ABT-751 in patients with advanced non-small cell lung cancer. J Thorac Oncol 2008;3:631-636.
12. Le Tourneau C, Lee JJ, Siu LL. Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst 2009;101:708-20. Epub 2009 May 12 Review.
13. Vale D. Veterinary co-operative oncology group - common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v 1.0. Vet Comp Oncol 2004;2:194-213.
14. Rusk A, Cozzi E, Stebbins M, et al. Cooperative activity of cytotoxic chemotherapy with antiangiogenic thrombospondin-1 peptides, ABT-526 in pet dogs with relapsed lymphoma. Clin Cancer Res 2006;12:7456-64.